Science of Coagulation

Blood coagulation is an important part of the host defense mechanism required for repair and maintenance of the circulatory system. This complex and multifactorial process has been described to contain two parallel but distinct pathways; hemostasis and thrombosis.

Learn More About Our Science

Why Factor XIa?

Factor XIa is a clinically-validated target for the prevention of thrombosis by selectively inhibiting the activation of the intrinsic (contact) pathway, without impacting normal hemostasis (bleeding) through the extrinsic pathway.

Learn More About Factor XIa

About EP-7041

  • eXIthera’s lead IV candidate EP-7041 is a novel, potent and selective small-molecule Factor XIa inhibitor
  • Completed Phase 1 demonstrating safety, tolerability and ideal clinical PK profile with validated efficacy marker aPTT
  • Established that effective anticoagulation is achievable with a small molecule therapeutic without the danger of increased bleeding risk or the need for a reversal agent
  • Preventing major bleeding events saves lives and will significantly reduce healthcare costs

News

Many innovative medicines are in the pipeline. But new funding approaches will be needed to make sure there is a greater chance that they are brought to market. Dr. Neil Hayward is included as one of PharmaVOICE‘s 130 industry experts and was posed 20 provocative questions, focusing on how influencers think about aspirational goals in terms […]
For more than a decade we have been discussing the role that technology and nontraditional partners would play to move the industry toward a more efficient business model — one based more on health outcomes than product sales. Dr. Neil Hayward is included as one of PharmaVOICE‘s 130 industry experts and was posed 20 provocative questions, […]